Biotech · Public company · Waltham, MA, US

Werewolf Therapeutics, Inc.

Ticker HOWL · SEC CIK 0001785530

Track this companyFree. Adds Werewolf Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials30 recruiting or active

Pipeline programs3From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline3

WTX-330Phase 2 · Advanced or Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
pembrolizumabPhase 1 · Metastatic Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
WTX-124Phase 1 · Metastatic Solid TumorClinicalTrials.gov · fetched Nov 12, 2026

A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or LymphomaPHASE1_PHASE2 · COMPLETED · started Apr 21, 2025ClinicalTrials.gov NCT06939283 · fetched Nov 12, 2026
WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomaPHASE1 · COMPLETED · started Dec 6, 2022ClinicalTrials.gov NCT05678998 · fetched Nov 12, 2026
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid TumorsPHASE1 · COMPLETED · started Aug 15, 2022ClinicalTrials.gov NCT05479812 · fetched Nov 12, 2026